AI assistant
Immuron Ltd — Report Publication Announcement 2021
Nov 2, 2021
35121_rns_2021-11-02_1ad51d7d-0080-4552-abb7-9dc7b90c34f9.pdf
Report Publication Announcement
Open in viewerOpens in your device viewer
==> picture [202 x 56] intentionally omitted <==
Immuron filed XBRL data with the SEC
Melbourne, Australia, November 3, 2021 : Immuron Limited (ASX: IMC; NASDAQ: IMRN) (“Immuron” or the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gutmediated pathogens, advises that, the Company is required by the Securities and Exchange Commission (SEC) to provide the Company’s financial statements in an interactive data format using eXtensible Business Reporting Language (XBRL).
The purpose of this release is to advise that further to the Form 20-F filing as announced on 29 October 2021, the Company has also filed the XBRL interactive data with the SEC, which is available via the company website at https://www.immuron.com.au/corporate-directory-and-governance/ .
This release has been authorised by the directors of Immuron Limited.
-
-
- END - - -
-
COMPANY CONTACT: Dr Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 [email protected]
Level 3, 62 Lygon Street, Carlton South, Victoria AUSTRALIA 3053
Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735
ABN: 80 063 114 045